Aragen Life Sciences (“Aragen”), a prestigious contract research organization (CRO) formerly known as GVK Biosciences, today announced that Goldman Sachs, an active investor in India , acquired a substantial minority stake in the company through the purchase of shares previously held by ChrysCapital and other pre-existing shareholders.
Aragen is a leading provider of outsourced services for discovery, development and manufacturing through the use of platforms based on small and large molecules. The company boasts an international clientele ranging from the United States to Europe and Japan.
The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.